Search / Trial NCT06221696

Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)

Launched by S.LAB (SOLOWAYS) · Jan 15, 2024

Trial Information

Current as of October 04, 2024

Completed

Keywords

Semaglutide Dietary Fiber Weight Loss Appetite Suppression

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Adults with a history of obesity or overweight and completed Semaglutide course.
  • * Age 18-65 years.-
  • Exclusion Criteria:
  • * Serious chronic illnesses.
  • * History of bulimia or anorexia.
  • * Pregnancy or lactation.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Novosibirsk, Novosibisk Region, Russian Federation

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0